The European Commission plans to launch a public consultation soon on its intention to revise the Cosmetic Products Regulation in line with Green Deal objectives and the Chemicals Strategy for Sustainability. Cosmetics Europe is gearing up for a battle to preserve the sector-specific approach embodied in the EU’s “gold standard” cosmetics regulations. Director-General John Chave discusses.
Toxicology faces an uncertain future in the EU as the Commission considers revising the Cosmetic Products Regulation to be more precautionary in its approach to hazardous chemicals and potentially eliminate the Scientific Committee on Consumer Safety’s role in assessing ingredient safety.
A growing host of “most hazardous” ingredients could be targeted for bans as the Commission moves to adapt regulations to...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
